What is Outcomes4me?
Outcomes4me operates at the intersection of healthcare technology and oncology, providing a sophisticated digital platform that empowers patients with personalized, evidence-based insights. As the first platform to integrate the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, the company provides a critical layer of transparency and clinical rigor. By allowing patients to securely input health data, the platform generates physician-reviewed treatment options, clinical trial matches, and genetic testing information. This approach not only improves patient outcomes but also streamlines the decision-making process for those navigating complex cancer care pathways, positioning the firm as a vital player in the digital health infrastructure.
How much funding has Outcomes4me raised?
Outcomes4me has raised a total of $37.8M across 4 funding rounds:
Other Financing Round
$4.7M
Debt
$149K
Series A
$12M
Other Financing Round
$21M
Other Financing Round (2020): $4.7M with participation from Sierra Ventures, Asset Management Ventures, and Merstal
Debt (2021): $149K led by PPP
Series A (2021): $12M supported by Merstal, Northpond Ventures, asset management ventures, IRA Capital, and Sierra Ventures
Other Financing Round (2025): $21M featuring Northpond Ventures, Sierra Ventures, and Silica Investments
Key Investors in Outcomes4me
Sierra Ventures
A Silicon Valley-based venture capital firm that raises dedicated funds to invest in early-stage technology startups, particularly in enterprise software, data/AI, and frontier tech.
Northpond Ventures
A firm dedicated to advancing science and technology by identifying and supporting breakthrough innovations that create significant impacts on humanity.
Silica Investments
A venture capital and private equity firm based in Victorville, California, focused on supporting high-growth potential companies.
What's next for Outcomes4me?
With the infusion of $21M, Outcomes4me is well-positioned to accelerate its product roadmap and expand its reach within the oncology sector. The strategic focus will likely center on deepening its integration with clinical systems and enhancing its AI capabilities to provide even more granular, real-time treatment insights. As the company moves beyond its current scaling phase, it is expected to prioritize partnerships with major healthcare providers and research institutions to further validate its clinical impact. By maintaining its commitment to regulatory-aligned, patient-centric technology, Outcomes4me is poised to set new standards for digital oncology support, potentially influencing broader trends in personalized medicine and patient-provider communication.
See full Outcomes4me company page
